Economic impact of thermostable vaccines.

[1]  Shawn T. Brown,et al.  Re-designing the Mozambique vaccine supply chain to improve access to vaccines. , 2016, Vaccine.

[2]  J. Stanaway,et al.  The global economic burden of dengue: a systematic analysis. , 2016, The Lancet. Infectious diseases.

[3]  E. Wimmer,et al.  Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine , 2016, PLoS pathogens.

[4]  Kimberly J. Hassett,et al.  Development of a highly thermostable, adjuvanted human papillomavirus vaccine. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  C. Karp,et al.  Evaluating the value proposition for improving vaccine thermostability to increase vaccine impact in low and middle-income countries. , 2015, Vaccine.

[6]  Shawn T. Brown,et al.  The Benin experience: How computational modeling can assist major vaccine policy changes in low and middle income countries. , 2015, Vaccine.

[7]  R. Hajjeh,et al.  Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013. , 2015, Vaccine.

[8]  G. Kang,et al.  Rotavirus gastroenteritis in India, 2011-2013: revised estimates of disease burden and potential impact of vaccines. , 2014, Vaccine.

[9]  Shawn T. Brown,et al.  The benefits of redesigning Benin's vaccine supply chain. , 2014, Vaccine.

[10]  K. Singh.  Economic evaluation of Japanese encephalitis vaccination programme in Uttar Pradesh, India: a cost-benefit study. , 2014, Journal of vector borne diseases.

[11]  D. Feikin,et al.  The effect of Haemophilus influenzae type B and pneumococcal conjugate vaccines on childhood meningitis mortality: a systematic review , 2013, BMC Public Health.

[12]  J. Scott,et al.  Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Kenyan Children , 2013, PloS one.

[13]  Chunling Lu,et al.  Comprehensive and integrated district health systems strengthening: the Rwanda Population Health Implementation and Training (PHIT) Partnership , 2013, BMC Health Services Research.

[14]  Shawn T. Brown,et al.  Augmenting Transport versus Increasing Cold Storage to Improve Vaccine Supply Chains , 2013, PloS one.

[15]  D. B. Miranda-Filho,et al.  Incremental costs of treating tetanus with intrathecal antitetanus immunoglobulin , 2013, Tropical medicine & international health : TM & IH.

[16]  Robert E Black,et al.  Global burden of childhood pneumonia and diarrhoea , 2013, The Lancet.

[17]  Li Zhang,et al.  Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China , 2013, BMC Health Services Research.

[18]  C. Mace,et al.  Adoption of revised dosage recommendations for childhood tuberculosis in countries with different childhood tuberculosis burdens. , 2012, Public health action.

[19]  Shawn T. Brown,et al.  The impact of making vaccines thermostable in Niger's vaccine supply chain. , 2012, Vaccine.

[20]  Shawn T. Brown,et al.  Impact of introducing the pneumococcal and rotavirus vaccines into the routine immunization program in Niger. , 2012, American journal of public health.

[21]  S. Hills,et al.  Estimated global incidence of Japanese encephalitis: a systematic review. , 2011, Bulletin of the World Health Organization.

[22]  Sheng-I Chen,et al.  Maintaining Vaccine Delivery Following the Introduction of the Rotavirus and Pneumococcal Vaccines in Thailand , 2011, PloS one.

[23]  K. Wannemuehler,et al.  Changing epidemiology of measles in Africa. , 2011, The Journal of infectious diseases.

[24]  Shawn T. Brown,et al.  Impact of changing the measles vaccine vial size on Niger's vaccine supply chain: a computational model , 2011, BMC public health.

[25]  C. F. Fischer Walker,et al.  Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size , 2011, BMC public health.

[26]  C. King,et al.  Measuring the burden of arboviral diseases: the spectrum of morbidity and mortality from four prevalent infections , 2011, Population health metrics.

[27]  S. Bae,et al.  Pulmonary impairment after tuberculosis and its contribution to TB burden , 2010, BMC public health.

[28]  S. Madhi,et al.  The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality , 2010, International journal of epidemiology.

[29]  J. Bresee,et al.  Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. , 2009, The Journal of infectious diseases.

[30]  M. Lucero,et al.  Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. , 2009, The Cochrane database of systematic reviews.

[31]  Rouslan Karimov,et al.  WHO and UNICEF estimates of national infant immunization coverage: methods and processes. , 2009, Bulletin of the World Health Organization.

[32]  Grace M. Lee,et al.  Cost-effectiveness of adult pertussis vaccination in Germany. , 2008, Vaccine.

[33]  J. Scott,et al.  Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya. , 2007, Bulletin of the World Health Organization.

[34]  K. Floyd,et al.  Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. , 2006, Bulletin of the World Health Organization.

[35]  U. Griffiths,et al.  Incremental cost-effectiveness of supplementary immunization activities to prevent neonatal tetanus in Pakistan. , 2004, Bulletin of the World Health Organization.

[36]  P Duclos,et al.  How best to estimate the global burden of pertussis? , 2003, The Lancet. Infectious diseases.

[37]  M Elizabeth Halloran,et al.  Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. , 2003, Vaccine.

[38]  P. Kilgore,et al.  Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. , 2003, Bulletin of the World Health Organization.

[39]  A. Harris,et al.  An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib‐HepB): a decision analytic approach to cost effectiveness , 2001, Australian and New Zealand journal of public health.

[40]  D. Jamison,et al.  Disease Control Priorities in Developing Countries , 1993 .

[41]  A. Prince,et al.  Epidemiology of hepatitis B infection in Liberian infants , 1981, Infection and immunity.

[42]  B. Heyworth,et al.  Diphtheria in the Gambia. , 1973, The Journal of tropical medicine and hygiene.

[43]  Tetanus vaccine , 2008 .

[44]  G. Hutton,et al.  The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. , 2005, Health policy and planning.